<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04170244</url>
  </required_header>
  <id_info>
    <org_study_id>3830</org_study_id>
    <nct_id>NCT04170244</nct_id>
  </id_info>
  <brief_title>Study of Skin Microbiome in Atopic Dermatitis Patients</brief_title>
  <official_title>Longitudinal &quot;Real-World&quot; Changes in Skin Microbial Ecology in AD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Everybody's skin has bacteria that normally lives on it. Previous research has shown that&#xD;
      people with eczema have higher concentrations of a certain bacteria (S. aureus), especially&#xD;
      when their disease is active. The purpose of this study is (a) to see if reductions in&#xD;
      another skin bacteria (C. acnes) plays a role in the overgrowth of S. aureus in eczema&#xD;
      patients, and (b) to examine how the types of bacteria present in the skin of patients with&#xD;
      eczema or psoriasis change with disease activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of colony forming units of Cutibacterium acnes (C. acnes)</measure>
    <time_frame>year 3</time_frame>
    <description>Skin swabs will be collected and cultured in anaerobic and aerobic conditions in the laboratory. The number of colonies of Cutibacterium acnes, Staphylococcus aureus and other coagulase-negative Staphylococci will be counted. The proportion of C. acnes relative to the other bacteria counted will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of colony forming units of Staphylococcus aureus (S. aureus)</measure>
    <time_frame>year 3</time_frame>
    <description>Skin swabs will be collected and cultured in anaerobic and aerobic conditions in the laboratory. The number of colonies of Cutibacterium acnes, Staphylococcus aureus and other coagulase-negative Staphylococci will be counted. The proportion of S. aureus relative to the other bacteria counted will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of colony forming units of other coagulase-negative Staphylococci</measure>
    <time_frame>year 3</time_frame>
    <description>Skin swabs will be collected and cultured in anaerobic and aerobic conditions in the laboratory. The number of colonies of Cutibacterium acnes, Staphylococcus aureus and other coagulase-negative Staphylococci will be counted. The proportion of other coagulase-negative Staphylococci relative to the other bacteria counted will be calculated.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin swab</intervention_name>
    <description>Skin will be swabbed to collect samples for bacterial analysis</description>
    <arm_group_label>Atopic Dermatitis</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Psoriasis</arm_group_label>
    <other_name>skin barrier function, skin biopsy (both optional)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All subjects will have skin swabs collected/banked and some subjects will also have serum&#xD;
      banked and optionally have skin biopsy collected and stored.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The healthy population will be defined as individuals with no personal history of or active&#xD;
        case of any atopic disorder (e.g. allergic rhinitis, allergic sinusitis, AD, allergic&#xD;
        asthma, or food allergy). These patients will be individuals seen in URMC Dermatology&#xD;
        clinic for a non-infectious condition that does not affect the skin of the extremities.&#xD;
&#xD;
        AD subjects must have moderate-to-severe disease defined as an Eczema Area and Severity&#xD;
        Index (EASI) of ≥ 12. The psoriasis subjects will have moderate-to-severe disease defined&#xD;
        as a Psoriasis Area and Severity Index of ≥ 7. The healthy controls will be recruited to be&#xD;
        age- and gender-matched to those with inflammatory skin diseases. Subjects will be&#xD;
        recruited from URMC Dermatology clinics at Red Creek and Collegetown.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥13 to 65 years of age (inclusive), male or female&#xD;
&#xD;
          -  Able to understand protocol and give consent&#xD;
&#xD;
          -  Able to keep clinic/study appointments and comply with study related procedures&#xD;
&#xD;
          -  Must be able to read, speak, and understand English&#xD;
&#xD;
          -  Chronic AD, according to the American Academy of Dermatology (AAD) Consensus Criteria,&#xD;
             that has been present for at least 1 year before the enrollment visit&#xD;
&#xD;
          -  Chronic PS, according to the AAD Consensus Criteria, that has been present for at&#xD;
             least 1 year before the enrollment visit.&#xD;
&#xD;
          -  AD subjects: have active lesions on upper extremities, lower extremities, or trunk and&#xD;
             a total disease severity of high moderate-to-severe (EASI ≥12)&#xD;
&#xD;
          -  PS subjects: have active lesions on upper extremities, lower extremities, or trunk and&#xD;
             a total disease severity of high moderate-to-severe (PASI ≥7)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling and/or unable to complete informed consent process&#xD;
&#xD;
          -  &lt;13 or &gt; 65 years of age&#xD;
&#xD;
          -  AD subjects: disease without upper extremity, lower extremity, or trunk lesions&#xD;
&#xD;
          -  AD subjects: total disease severity less than moderate (EASI &lt;12), depending on&#xD;
             enrollment&#xD;
&#xD;
          -  PS subjects: disease without upper extremity, lower extremity, or trunk lesions&#xD;
&#xD;
          -  PS subjects: total disease severity less than moderate (PASI &lt;7), depending on&#xD;
             enrollment&#xD;
&#xD;
          -  Control subjects: diagnosed with an inflammatory skin disease&#xD;
&#xD;
          -  Severe concomitant illness(es) that, in the investigator's judgment, would adversely&#xD;
             affect the individual's participation in the study (Ex: HIV infection, autoimmune&#xD;
             disease, severe heart failure, Hx of malignancy (other than in situ cervical cancer or&#xD;
             basosquamous skin cancer), etc.)&#xD;
&#xD;
          -  Recent bacterial, fungal, or viral infection requiring systemic therapies (PO, IV or&#xD;
             IM) within the last month.&#xD;
&#xD;
          -  Patients with a history of keloid formation or lidocaine allergy may be enrolled but&#xD;
             cannot undergo optional skin biopsies.&#xD;
&#xD;
          -  Patients with a history of serious life-threatening reaction to tape or adhesives may&#xD;
             be enrolled but cannot undergo optional TEWL measurements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa A Beck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Beck, MD</last_name>
    <phone>585-275-7546</phone>
    <email>lisa_beck@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia Papalia, BA</last_name>
    <phone>585-273-4195</phone>
    <email>Alicia_papalia@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Beck, MD</last_name>
      <phone>585-275-7546</phone>
      <email>lisa_beck@urmc.rochester.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Lisa Beck</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>staphylococcus, microbiome, atopic dermatitis, cutibacterium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

